The science behind the clinical success of EXOGEN
Learn more about the mechanism of action of Exogen and how this can overcome some barrier to healing.
Andrew Harrison PhD is the Director of Research for Bioventus. Andrew has been working as a bone & cartilage biologist for the past 25 years. He completed his PhD on the differentiation of mesenchymal stem cells at Manchester University. He started his career at the Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry in the United Kingdom. During his 5 years at the orthopaedic hospital in Oswestry he researched areas including osteoporosis, ankylosing spondylitis, and raised antibodies to cartilage matrix proteins.
In 1995 Andrew joined Smith & Nephew leading numerous projects involving BMP binding proteins, novel small molecules for fracture repair and investigating new implant surfaces. In 2004 Andrew accepted the position to uncover the mechanism of action of EXOGEN®. In doing this he led an internal team and managed external collaborations in Europe, US and Asia. The mechanism of action of EXOGEN® continues to develop and Andrew keeps abreast of the latest developments with his contacts through an open innovation process. In 2012 the Biologics arm of Smith & Nephew was sold to Essex Woodland in the US creating Bioventus, and as part of this EXOGEN® was moved from Smith & Nephew to Bioventus.
Andrew is a member of a number of orthopaedic societies including Orthopaedic Research Society (ORS), British Orthopaedic Research Society (BORS), Osteoarthritis Research Society International (OARSI) and British Society for Matrix Biology (BSMB).
The symposium is organized and supported by Bioventus.